ARADIGM CORP Uncategorized Contracts & Agreements

31 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Bidding Procedures
ARADIGM CORP
Pharmaceuticals
2020
AMENDMENT TO GOVERNANCEAGREEMENT
ARADIGM CORP
Pharmaceuticals
2016
ATTACHMENT A
ARADIGM CORP
Pharmaceuticals
CA
2014
GOVERNANCE AGREEMENT by and between ARADIGM CORPORATION and GRIFOLS, S.A. Dated as of [ ], 2013 TABLE OF CONTENTS
ARADIGM CORP
Pharmaceuticals
CA
2013
ARADIGM CORPORATION
ARADIGM CORP
Pharmaceuticals
CA
2011
FINANCIAL STATEMENTS
ARADIGM CORP
Pharmaceuticals
CA
2009
FINANCIAL STATEMENTS
ARADIGM CORP
Pharmaceuticals
CA
2009
FINANCIAL STATEMENTS
ARADIGM CORP
Pharmaceuticals
CA
2009
FINANCIAL STATEMENTS
ARADIGM CORP
Pharmaceuticals
CA
2009
4,000,000 Shares
ARADIGM CORP
Pharmaceuticals
NY
2009
40,663,071 Shares
ARADIGM CORP
Pharmaceuticals
NY
2009
Current assets
ARADIGM CORP
Pharmaceuticals
CA
2008
Current assets
ARADIGM CORP
Pharmaceuticals
2008
Current assets
ARADIGM CORP
Pharmaceuticals
NY
2008
Current assets
ARADIGM CORP
Pharmaceuticals
CA
2007
Current assets
ARADIGM CORP
Pharmaceuticals
NY
2007
AMENDMENT NO. 3 TO RIGHTS AGREEMENT BETWEEN ARADIGM CORPORATION AND COMPUTERSHARE TRUST COMPANY, N.A.
ARADIGM CORP
Pharmaceuticals
2007
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
CA
2007
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
NY
2007
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
CA
2006
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
DE
2006
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
CA
2006
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
DE
2006
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
2006
We intend to develop a proprietary portfolio of respiratory disease therapies, where we apply our delivery and formulation technologies to existing drugs to provide a superior...
ARADIGM CORP
Pharmaceuticals
CA
2006
Current assets
ARADIGM CORP
Pharmaceuticals
CA
2006
In thousands, except shares data
ARADIGM CORP
Pharmaceuticals
CA
2004
Novo Nordisk A/S, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and
ARADIGM CORP
Pharmaceuticals
2002
Novo Nordisk A/S, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and
ARADIGM CORP
Pharmaceuticals
CA
2002
EXHIBIT 10.15B
ARADIGM CORP
Pharmaceuticals
2002
EXHBIIT 10.15A
ARADIGM CORP
Pharmaceuticals
2002